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Objectives: Within the National Institute for Health and Care Excellence (NICE) 
Appraisal process, quality adjusted life years (QALYs) are regarded as having equal 
weighting. However, in January 2009, NICE introduced the end-of-life (EOL) crite-
ria, giving more weight to QALYs for life-extending, and EOL interventions. In May 
2014, the Scottish Medicines Consortium (SMC) introduced the Patient and Clinician 
Engagement (PACE) process for evaluating EOL medicines and medicines used to 
treat very rare conditions, to allow a more flexible approach to considering such 
medicines. These two initiatives allow a greater cost per QALY gained willingness-
to-pay threshold than usual in the United Kingdom (UK), however there are differ-
ences in their requirements and outcomes. The aim of this study was to compare 
the process and conclusions drawn by NICE and the SMC for health technology 
appraisal submissions either meeting NICE EOL criteria after May 2014, or being 
accepted into the PACE process based on EOL. MethOds: All technologies reviewed 
under the PACE process, NICE EOL criteria or both were identified. Information 
collected included whether EOL criteria were met, incremental cost effectiveness 
ratio (ICER) and SMC and NICE decisions. Results: In total, 15 technologies were 
reviewed. Of the 15, 14 were reviewed under PACE; 8 were given positive SMC Advice, 
3 were given restricted positive SMC Advice and 3 were given negative SMC Advice. 
Of the 14 technologies reviewed under the PACE process, 7 were reviewed by NICE, 
4 met EOL criteria, 2 of which were given positive NICE Guidance. cOnclusiOns: 
Of those technologies considered by both NICE and SMC since May 2014, fewer met 
the NICE EOL criteria than the PACE EOL criteria, and fewer still received positive 
NICE Guidance. There are differences in access to interventions for diseases with 
short life expectancies within the UK, although further research into the changing 
Cancer Drugs Fund is needed.
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Objectives: To analyse the causes and financial implications of the variabil-
ity of use of A&E resources (visits, admissions) across Spanish Hospitals and 
Regions MethOds: Review of the Configuration Management DataBase Set (CMDB) 
and Hospital Discharge Statistics during the period 2010-2012, using a multivari-
ate analyses controlling for factors like: region, sex, age, income, etc. to explain 
the relative rate to average and variations within and between regions. Results: 
There is a significant variation between and within regions and hospitals, which 
is mostly explained by personal income, distance to hospitals, availability of alter-
natives in Primary Care, and, quite interestingly (p< 0.05 within Hospitals of same 
regions), size of hospital measured in terms of available beds. This impacts on the 
resource allocation, new hospitals to be erected -new investments- and cost per 
patient. cOnclusiOns: Variability of A&E resource utilisation (frequency of visits, 
hospitalizations) is greatly explained using a multidimensional approach within and 
betwen regions, having more than 80% explanative variables laying into Personal 
Income, Distance to Hospital, Available Beds, and Primary Care Ambulatory alterna-
tives. Other variables were not deemed to be significant.
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Objectives: Differential pricing (DPR) is based on the economic concept of price 
discrimination. DPR is reported as a potential effective way to: (1) Improve access to 
medicines in lower income countries whilst maintaining welfare in higher income 
countries; (2) Preserve incentives for R&D through higher prices in high income 
countries. This study aimed to assess the current situation of DPR for pharmaceu-
ticals in the European Union (EU). MethOds: A literature review was conducted 
in MEDLINE®, WHO, OECD, and EU Commission websites, complemented by a grey 
literature search. Key DPR principles were identified and current implementation 
challenges in the EU were assessed. Results: Ramsey (1927) developed a well-
known DPR theory stating that prices should differ across markets according to 
inverse relation to demand elasticity, with more price-sensitive users, (i.e. lower 
income countries) charged at a lower price than less-price sensitive users. Another 
approach to DPR proposed by Danzon et al. (2013), called “value-based differential 
pricing”, would be to have prices reflecting utilization in each country. DPR is highly 
discussed among national/EU institutions and industry given the differences in 
GDP per capita and price levels of EU countries. However, several challenges were 
reported to limit DPR implementation: (1) DPR scheme is based on average per capita 
income; (2) Manufacturers attempt to apply higher price in low income markets 
and lower price in high income markets; (3) Differential distribution margins; (5) 
Risk of parallel trade; (6) Use of external reference pricing (ERP) where prices and 
undisclosed rebates in high income countries drive high prices in lower income 
countries. cOnclusiOns: DPR is widely debated to enhance access to innova-
tive expensive medicines in the low income market. However, DPR optimization 
requires wide coordination and interaction, between the countries and the industry 
to minimize various counteracting policies and initiatives.
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Objectives: One of the most significant effects of economic crisis in Greece is the 
rising number of unemployed and uninsured citizens. A large percentage of the 
attempt to identify barriers to access. This study aims to investigate the factors 
that act as determinants of HSU for the Greek population, as well as highlight 
their evolution since 2006. MethOds: The study was based on data collected by 
three cross-sectional health interview surveys conducted by the National School of 
Public Health, Athens, Greece, in 2006, 2011 and 2015 with representative national 
samples of 4003, 6569 and 2012 adults respectively. Respondents were asked to 
answer a series of questions on HSU and report their demographic characteris-
tics. Results: A significant decrease in the basic measures of HSU between 2006 
and 2015 was detected. In 2006, 74.6% of respondents answered that they had used 
a health service in the last 12 months, whereas in 2015 the corresponding figure 
was only 46.5%. There was a statistically significant association between HSU and 
gender of respondents, with females utilizing the services at a considerably higher 
rate (52.9%) than men (38.6%). The degree of non utilization health services was 
not changed substantially in these surveys, however the reasons for not using the 
services were found to change and brought up statistically significant associa-
tions with age, income and occupation of respondents. It is noteworthy that the 
percentage of population unable to access healthcare due to inability to pay was 
5.9%, 8.5% and 27.4% in 2006, 2011 and 2015 respectively. cOnclusiOns: It is 
evident that demographic and socioeconomic determinants influence the HSU. 
The findings highlight the problem of social inequalities as a major issue of health 
policy.
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Objectives: Access to medicines is usually given under the regulatory approvals and 
subsequent coverage decisions, after efficacy and safety have been proven by clinical 
trials. Recently, systems to enable exceptional early access have been explored to meet 
significant, unmet, and urgent medical needs for frontier medicines. In Japan, the 
Advanced Medical Care B system (AMCB) is already in operation. Two other systems, 
the Compassionate Use system (CU) and the Patient-Initiated Mixed-Care system 
(PIMC), are planned to start. The objective of this study is to understand the design and 
institutional positioning of these three systems, identifying opportunities for further 
improvements. MethOds: A documentary research was conducted by analyzing 
government documents and the Diet Record. Results: For the AMCB system, the 
review board designates technologies that include the use of unapproved medicines 
or off-label indications, after requests from health care professionals. The CU sys-
tem is to be fully introduced in 2015 and targets medicines at later stages of clinical 
development, opening up opportunities for patients who are not eligible for the tri-
als. The PIMC system is to start in 2016 and focused on medicines or patients that 
are not covered by the other two systems. The three systems have no legal financial 
aid programs to cover the costs of experimental medicines, while the systems allow 
coverage of other treatment costs than those medicines. Details of the CU and PIMC 
systems are currently under discussion. cOnclusiOns: The scopes of the three 
systems were found to be complementary to one another, covering both unapproved 
medicines and patients excluded from clinical studies. Legal financial aid would be 
worth considering for more equitable and extensive early access.
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Objectives: China’s New Medical Reform (NMR), which started in 2009, aims at 
improving the equity of basic health service, especially in the less well-off areas. 
The purpose of this study is to know whether the popularity of NMR has allevi-
ate the existing health inequity in rural West China by comparing indicators of 
health equity of rural residents covered by New Rural Cooperative Medical System 
(NRCMS) before and after China’s NMR. MethOds: Related data have been col-
lected respectively from 2860 and 2432 rural residents through random-sampling 
household questionnaire survey in Z County, Shaanxi, China, in November 2009 
(before NMR) and October 2012 (after NMR). The sample residents are divided 
into 5 groups by per capita annual income in families, and equity of health need, 
utilization and benefit have been calculated through Concentration Index (CI) and 
ANOVA. Results: On equity of health need, CIs for two-week morbidity and half-
year prevalence rate of chronic diseases among rural residents of different income 
levels in 2009 and 2012 are -0.0524, -0.0536 and -0.0792, -0.0840 respectively. On 
equity of health service utilization, CIs for treatment of two-week morbidity in 
2009 and 2012 are -0.0096 and -0.0992 respectively; CIs for hospitalization and non-
hospitalization of residents are 0.0032, -0.1712 and -0.0396, -0.1548 respectively. 
On benefit equity, CIs for hospitalization rate of residents in 2009 and 2012 are 
-0.0208 and -0.0712 respectively; CIs for average compensation of hospitaliza-
tion are -0.0212 and -0.1620 respectively. Difference in economic burden caused 
by diseases among residents of different income levels is non-significant after 
the implementation of NMR (P> 0.05). cOnclusiOns: NMR has improved the 
equity of health service need of rural residents to some extent while reduced 
the utilization equity little. Benefit equity is enhanced since low-income resi-
dents benefit more than high-income counterparts from in-patient health service. 
Rural residents’ economic burden caused by diseases has reduced significantly 
after NMR.
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